Your browser doesn't support javascript.
loading
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.
Nooka, A K; Kaufman, J L; Muppidi, S; Langston, A; Heffner, L T; Gleason, C; Casbourne, D; Saxe, D; Boise, L H; Lonial, S.
Afiliación
  • Nooka AK; Department of Hematology and Medical Oncology Winship Cancer Center, Emory University, Atlanta, GA, USA.
  • Kaufman JL; Department of Hematology and Medical Oncology Winship Cancer Center, Emory University, Atlanta, GA, USA.
  • Muppidi S; Department of Hematology and Medical Oncology Winship Cancer Center, Emory University, Atlanta, GA, USA.
  • Langston A; Department of Hematology and Medical Oncology Winship Cancer Center, Emory University, Atlanta, GA, USA.
  • Heffner LT; Department of Hematology and Medical Oncology Winship Cancer Center, Emory University, Atlanta, GA, USA.
  • Gleason C; Department of Hematology and Medical Oncology Winship Cancer Center, Emory University, Atlanta, GA, USA.
  • Casbourne D; Department of Hematology and Medical Oncology Winship Cancer Center, Emory University, Atlanta, GA, USA.
  • Saxe D; Department of Pathology, Emory University School of Medicine, Atlanta, GA, USA.
  • Boise LH; Department of Hematology and Medical Oncology Winship Cancer Center, Emory University, Atlanta, GA, USA.
  • Lonial S; Department of Hematology and Medical Oncology Winship Cancer Center, Emory University, Atlanta, GA, USA.
Leukemia ; 28(3): 690-3, 2014 Mar.
Article en En | MEDLINE | ID: mdl-24220275
Prior studies have shown that myeloma patients exhibiting either genetically defined high-risk disease or plasma cell leukemia have a poor outcome with a median overall survival (OS) of ≤3 years. Results of IFM 2005-01 and 02 suggest that relatively limited bortezomib-containing induction regimens did not produce a major survival benefit among these patients. However, results of recent studies suggest that combination therapy may benefit these patients when given early and again later in the treatment. We evaluated a combination maintenance/consolidation regimen (RVD) following autologous stem cell transplant (ASCT) for high-risk patients to evaluate the impact of this approach on outcome. Following initiation of RVD maintenance, 51% of patients achieved stringent complete response (sCR), with 96% achieving at least VGPR as best response. Median progression free survival (PFS) for all patients is 32 months with a 3-year OS of 93%. The regimen was well tolerated with no grade 3/4 neuropathy. Early ASCT followed by RVD maintenance is a promising strategy for high-risk myeloma patients and delivered excellent response rates, and promising PFS and OS.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiple Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiple Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido